))
#2 - A biomaterial-based vaccine
Manage episode 429175496 series 3586580
Innhold levert av Accelerating Cancer Immunotherapy Research (ACIR). Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Accelerating Cancer Immunotherapy Research (ACIR) eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
In this 2nd episode, our co-hosts discuss the use of a macro-scale material to co-deliver GMCSF and CpG, both APC stimulating agents, as well as AML antigens to kill AML cells.
GUEST: Alex Najibi is now a postdoctoral fellow at Harvard School of Engineering and Applied Sciences, studying bioengineering in David Mooney's lab.
Original study => https://pubmed.ncbi.nlm.nih.gov/31937942/
Thanks for listening! Let’s stay in touch:
- Tweet us at @ImmunoTalks
- Share our episodes on LinkedIN and Instagram
- Email us at contact@acir.org
Kapitler
1. #2 - A biomaterial-based vaccine (00:00:00)
2. Background about the study (00:00:29)
3. GUEST: Alex Najibi (00:05:30)
3 episoder
Del
